An update on respiratory syncytial virus antiviral agents

Bibliography

• DE CLERCQ E: Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Int. J. Antimicrob. Agents (1996) 7:193–202.
   PubMed Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• WYDE PR: Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. (1998) 39:63–79.
   PubMed Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• WYDE PR: Chemotherapy of respiratory viruses: prospects and challenges. Drug Resist. Updates (1999) 2:244–258.
   PubMed Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• PRINCE GA: Respiratory syncytial virus antiviral agents. Exp. Opin. Ther. Patents (1999) 9:753–762.
   Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• SHIGETA S: Recent progress in antiviral chemotherapy for respiratory syncytial virus infections. Exp. Opin. Invest. Drugs (2000) 9:221–235.
   PubMed Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• GAZUMYAN A, MITSNER B, ELLESTAD GA: Novel anti-RSV dianionic den drimer -like compounds: design, synthesis and biological evaluation. Curr. Pharm. Design (2000) 6:525–546.
   PubMed Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• MEANWELL NA, KRYSTAL M: Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discov. Tod. (2000) 5:241–252.
   PubMed Web of Science ®Google Scholar
• •Review of RSV antivirals pre-dating those described in the current review.
   Google Scholar
• COLLINS PC, MCINTOSH K, CHANOCK RM: Respiratory syncytial virus. In: Fields Virology (3rd Edition). Fields BN, Knipe DM, Howley PM et al. (Eds.), Lippincott-Raven Publishers, Philadelphia, USA (1996):1313–1351.
   Google Scholar
• KARRON RA, BUONAGURIO DA, GEORGIU AF et al.: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Nat. Acad. Sci. USA (1997) 94:13961–13966.
   PubMed Web of Science ®Google Scholar
• FELDMAN SA, AUDET S, BEELER JA: The fusion glycopro-tein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Virol. (2000) 74:6442–6447.
   PubMed Web of Science ®Google Scholar
• PRINCE GA, PRIEELS J-P, SLAOUI M, PORTER DD: Histologic profiles of primary respiratory syncytial virus (RSV) infection, reinfection and vaccine-enhanced RSV disease in the cotton rat (Sigmodon hispidus). Lab. Invest. (1999) 79:1385–1392.
   PubMed Web of Science ®Google Scholar
• ••Differentiation of histopathology in the lungs of animalsimmunised with formalin-inactivated RSV versus those undergoing primary or secondary infection.
   Google Scholar
• BOURGEOIS C, BOUR JB, LIDHOLT K, GAUTHRAY C, POTHIER P: Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J. Viral. (1998) 72:7221–7227.
   PubMed Web of Science ®Google Scholar
• FELDMAN SA, HENDRY RM, BEELER JA: Identification of a linear heparin binding domain for human respira-tory syncytial virus attachment glycoprotein G. J. Vim/. (1999) 73:6610–6617.
   Web of Science ®Google Scholar
• MARTINEZ I, MELERO JA: Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. j Gen. Viral. (1998) 79:2215–2220.
   PubMed Web of Science ®Google Scholar
• PLOTNICKY-GILQUIN H, GOETSCH L, HUSS T et al.: Identification of multiple protective epitopes (protec-topes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Viral. (1999) 73:5637–5645.
   PubMed Web of Science ®Google Scholar
• PASTERY MK, GOWER TL, SPEARMEN PW, CROWE JE, JR., GRAHAM BS: A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus Type 3. Nature Med. (2000) 6:35–40.
   Google Scholar
• DING W-D, MITSNER B, KRISHNAMURTHY G et al.: Novel and specific respiratory syncytial virus inhibitors that target virus fusion. J Med. Chem. (1998) 41:2671–2675.
   PubMed Web of Science ®Google Scholar
• WYDE PR, MOORE-POVEDA DK, O'HARA B, DING W-D, MITSNER B, GILBERT BE: CI387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res. (1998) 38:31–42.
   PubMed Web of Science ®Google Scholar
• AULABAUGH A, DING W-D, ELLESTAD GA et al.: Inhibi-tion of respiratory syncytial virus by a new class of chemotherapeutic agents. Drugs of the Future (2000) 25:287–294.
   Google Scholar
• KIMURA K, MORI S, TOMITA K et al.: Antiviral activity of NMS03 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res. (2000) 47:41–51.
   PubMed Web of Science ®Google Scholar
• JOHNSON S, GRIEGO SD, PFARR DS et al.: A direct comparison of the activities of two humanized respira-tory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J. Infect. Dis. (1999) 180:35–40.
   PubMed Web of Science ®Google Scholar
• ••A head-to-head study, both in vitro and in vivo, suggestingthe reasons for the different outcomes of clinical trials of two anti-RSV mAbs.
   Google Scholar
• RODRIGUEZ WJ, GRUBER WC, WELLIVER RC et al.: Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics (1997) 99:454–461.
   PubMed Web of Science ®Google Scholar
• •Important clinical trial of therapeutic IVIG, high risk patients.
   Google Scholar
• RODRIGUEZ WJ, GRUBER WC, GROOTHUIS JR et al.: Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in healthy children. Pediatrics (1997) 100:937–942.
   PubMed Web of Science ®Google Scholar
• •Important clinical trial of therapeutic IVIG, normal risk patients.
   Google Scholar
• DEVINCENZO JR, HIRSCH RL, FUENTES RJ, TOP FH, JR.: Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience. Bone Marrow Transplant. (2000) 25:161–165.
   Google Scholar
• •IVIG in the therapy of RSV infection in bone marrow transplant patients.
   Google Scholar
• MEISSNER HC, WELLIVER RC, CHARTRAND SA et al.: hnmunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr. Infect. Dis. J. (1999) 18:223–231.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial leading to licensure of RSV mAb.
   Google Scholar
• MALLEY R, DEVINCENZO J, RAMILO 0 et al.: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. (1998) 1 78:1555–1561.
   Google Scholar
• •Important clinical trial of therapeutic mAb, intubated patients.
   Google Scholar
• PIEDIMONTE G, KING KA, HOLMGREN NL, BERTRAND PJ,RODRIGUEZ MM, HIRSCH RL: A humanized monoclonal antibody against respiratory syncytial virus (palivizu-mab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr. Res. (2000) 47:351–356.
   PubMed Web of Science ®Google Scholar
• PRINCE GA, MATHEWS A, CURTIS S, PORTER DD: Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model using systemi-cally administered monoclonal antibody (palivizu-mab) and glucocorticosteroid. J Infect. Dis. (2000) 182:1326–1330.
   Web of Science ®Google Scholar
• ••Demonstration that combined anti-viral/anti-inflammatorytherapy reduces viral titres while simultaneously reversing pulmonary histopathology.
   Google Scholar
• MEISSNER HC, GROOTHUIS JR, RODRIGUEZ WJ et al.: Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209863) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob. Agents Chemother. (1999) 43:1183–1188.
   PubMed Web of Science ®Google Scholar
• WELTZIN R, MONATH TP: Intranasal antibody prophy-laxis for protection against viral disease. Clin. Microbial Rev. (1999) 12:383–393.
   PubMed Web of Science ®Google Scholar
• DELAGRAVE S, CATALAN J, SWEET, C et al.: Effects ofhumanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Engineering (1999) 12:357–362.
   PubMedGoogle Scholar
• BOURGEOIS C, HOUR JB, AHO LS, POTHIER P: Prophy-lactic administration of a complemen tarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Viral. (1998) 72:807–810.
   PubMed Web of Science ®Google Scholar
• HEARD C, BRAMS P, WALSH E et al.: Two neutralizinghuman anti-RSV antibodies: cloning, expression and characterization. Mol. Med. (1999) 5:35–45.
   PubMed Web of Science ®Google Scholar
• CROWE JE, JR., GILMOUR PS, MURPHY BR et al.: Isolationof a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J. Infect. Dis. (1998) 177:1073–1076.
   Google Scholar
• CROWE JE, JR., FIRESTONE C-Y, GRIM R etal.: Monoclonalantibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody Fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology (1998) 252:373–375.
   Google Scholar
• VENTURA F, CHESEAUX JJ, COTTING J, GUIDNARD JP:Respiratory syncytial virus infections and ribavirin treatment. Clinical and economic evaluation. Arch. Pediatr. (1998) 5:123–131.
   PubMed Web of Science ®Google Scholar
• •Clinical study suggesting a detrimental effect of ribavirin.
   Google Scholar
• GUERGUERIAN A-M, GAUTHIER M, LEBEL MH, FARRELL CA, LACROIX J: Ribavirin in ventilated respiratory syncytial virus bronchiolitis. Am. J. Respir. Grit. Care Med. (1999) 160:829–834.
   PubMed Web of Science ®Google Scholar
• •Clinical study showing neither beneficial nor detrimental effects of ribavirin in ventilated patients.
   Google Scholar
• EDELL D, BRUCE E, HALE K, EDELL D, KHOSHOO V: Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a prelimi-nary report. Pediat. Pulmonol (1998) 25:154–158.
   PubMed Web of Science ®Google Scholar
• •Suggestion that reactive airway disease following severe RSV infection may be reduced in patients treated with ribavirin.
   Google Scholar
• RODRIGUEZ WJ, ARROBIO J, FINK R, KIM HW, MILBURN C: Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Arch. Pediatr. Adolesc. Med. (1999) 153:469–474.
   PubMed Web of Science ®Google Scholar
• •Long term (7 years) follow-up of ribavirin-treated patients suggesting a reduction in reactive airway disease.
   Google Scholar
• MCCARTHY AJ, KINGMAN HM, KELLY C et al.: Theoutcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplanta-tion. Bone Marrow Transplant. (1999) 24:1315–1322.
   PubMed Web of Science ®Google Scholar
• MANGI MH, AITKEN C, NEWLAND AC: Outbreak of respiratory syncytial virus infection in adult bone marrow transplant unit: role of ribavirin treatment and recommendations for prevention of RSVinfection in high risk patients. Blood (1998) 92:334B–335B.
   Google Scholar
• MCCOLL MD, CORSER RB, BREMNER J, CHOPRA R: Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. (1998) 21:423–425.
   PubMed Web of Science ®Google Scholar
• ADAMS RH, CHRISTENSON JC, PETERSEN FB, BEATTY PG:Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant. (1999) 24:661–664.
   PubMed Web of Science ®Google Scholar
• GHOSH S, CHAMPLIN RE, ENGLUND J et al: Respiratorysyncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. (2000) 25:751–755.
   PubMed Web of Science ®Google Scholar
• •Clinical study suggesting reduced mortality in RSV-infected bone marrow transplant patients who were treated with ribavirin and immunoglobulin simultaneously.
   Google Scholar
• MARKLAND W, MCQUAID TJ, JAIN J, KWONG AD: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. (2000) 44:859–866.
   PubMed Web of Science ®Google Scholar
• PLAYER MR, BARNARD DL, TORRENCE PF: Potent inhibi-tion of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Nail. Acad. Sci. USA (1998) 95:8874–8879.
   PubMed Web of Science ®Google Scholar
• BARNARD DL, SIDWELL RW, XIAO W, PLAYER MR, ADAHSA, TORRENCE PF: 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleo tide structure modifications and RNA target site selection. Antiviral Res. (1999) 41:119–134.
   PubMed Web of Science ®Google Scholar
• PIRAINO F, BRANDT CR: Isolation and partial charac-terization of an antiviral, RC-183, from the edible mushroom Rozites caperate. Antiviral Res. (1999) 43:67–78.
   PubMed Web of Science ®Google Scholar
• CHEN JL, BLANC P, STODDART CA et al.: New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus. J. Nat. Prod. (1998) 61:1295–1297.
   PubMed Web of Science ®Google Scholar
• KOTT V, BARBINI L, CRUANES M et al.: Antiviral activity in Argentine medicinal plants. J. Ethnopharm. (1999) 64: 79–84.
   PubMed Web of Science ®Google Scholar
• DOMACHOWSKE JB, BONVILLE CA, DYER KD, ROSENBERG HF: Evolution of antiviral activity in the ribonuclease A gene superfamily: evidence for a specific interaction between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus. Nucleic Acids Res. (1998) 26:5327–5332.
   PubMed Web of Science ®Google Scholar
• DOMACHOWSKE JB, DYER KD, BONVILLE CA, ROSENBERG HF: Recombinant human eosinophil-derived neurotoxin/RNAse 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect. Dis. (1998) 177:1458–1464.
   PubMed Web of Science ®Google Scholar
• WATANABE W, SUDO K, SATO R et al.: Novel anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives. Biochem. Biophys. Res. Comm. (1998) 249:922–926.
   PubMed Web of Science ®Google Scholar
• SUDO K, WATANABE W, KONNO K et al.: Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob. Agents Chemother. (1999) 43:752–757.
   PubMed Web of Science ®Google Scholar
• TRIPP RA, MOORE D, ANDERSON LJ: TI-11- and TI-12-type cytokine expression by activated T lymphocytes from the lung and spleen during the inflammatory response to respiratory syncytial virus. Cytokine (2000) 12:801–807.
   PubMed Web of Science ®Google Scholar
• VAN SCHAIK SM, OBOT N, ENHORNING G et al.: Role ofinterferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med. Viral. (2000) 62:257–266.
   PubMed Web of Science ®Google Scholar
• VAN SCHAIK SM, WELLIVER RC, KIMPEN JLL: Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatric Pulmonol. (2000) 30:131–138.
   PubMed Web of Science ®Google Scholar
• •Overview of cytokine and chemokine responses in RSV infection.
   Google Scholar
• WELLIVER RC: Chemokines, cytokines and inflamma- tory cells in respiratory syncytial virus infection: similarities to allergic responses. Pediat. Asthma, Allergy, Immunol. (2000) 14:93–100.
   Google Scholar
• •Overview of cytokine and chemokine responses in RSV infection.
   Google Scholar
• THURAU AM, STRECKERT HJ, RIEGER CHL, SCHAUER U: Increased number of Tcells committed to IL-5 produc-tion after respiratory syncytial virus (RSV) infection of human mononuclear cells in vitro. Clin. Exp. 1177177111701 (1998) 114:450–455.
   Google Scholar
• HORNSLETH A, KLUG B, NIR, M et al.: Severity of respira-tory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopha-ryngeal secretions. Pediatr. Infect. Dis. J. (1998) 17:1114–1121.
   PubMed Web of Science ®Google Scholar
• MASTRONARDE JG, MONICK MM, MUKAIDA N, MATSUSHIMA K, HUNNINGHAKE GW: Activator protein-I is the preferred transcription factor for cooperative interaction with nuclear factor-KB in respiratory syncytial virus-induced interleukin-8 gene expression in airway epithelium. J Infect. Dis. (1998) 177:1275–1281.
   PubMed Web of Science ®Google Scholar
• HARRISON AM, BONVILLE CA, ROSENBERG HF, DOMACHOWSKE JB: Respiratory syncytial virus-induced chemokine expression in the lower airways. Eosinophil recruitment and degranulation. Am. J Respir. Grit. Care Med. (1999) 159:1918–1924.
   PubMed Web of Science ®Google Scholar
• BECKER S, SOUKUP JM: Airway epithelial cell-inducedactivation of monocytes and eosinophils in respira-tory syncytial viral infection. imimmobio/ogy (1999) 201:88–106.
   Google Scholar
• PIEDIMONTE G, RODRIGUEZ MM, KING KA, MCLEAN S,JIANG X: Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am. J. Physiol. (1999) 277:L831–L840.
   PubMed Web of Science ®Google Scholar
• WANG S-Z, FORSYTH KD: The interaction of neutro-phils with respiratory epithelial cells in viral infection. Respirology (2000) 5:1–9.
   PubMedGoogle Scholar
• OPENSHAW PJM, PALA P, SPARER T, MATTHEWS S, PENNYCOOK A, HUSSELL T: T-cell subsets and lung inflammation: lessons from respiratory syncytial virus. Eur. Respir. Rev. (2000) 1 0 :108–111.
   Google Scholar
• •Overview of cellular immune responses in RSV infection.
   Google Scholar
• MALLEY R, VERNACCHIO L, DEVINCENZO J et al.: Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. Pediatr. Infect. Dis. j (2000) 19:1–7.
   PubMed Web of Science ®Google Scholar
• BULOW SM, NIR M, LEVIN E et al.: Pr ednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics (1999) 104:e77.
   PubMed Web of Science ®Google Scholar
• •Clinical study of corticosteroid treatment of RSV disease showing neither a beneficial nor a detrimental effect.
   Google Scholar
• WONG JYW, MOONS, BEARDSMORE C, O'CALLAGHAN C, SIMPSON H: No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis. Eur. Respir. J. (2000) 15:388–394.
   PubMedGoogle Scholar
• CADE A, BROWNLEE KG, CONWAY SP etal.: Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch. Dis. Child. (2000) 82:126–130.
   Google Scholar
• GOEBEL J, ESTRADA B, QUINONEZ J, NAGJI N, SANFORD D, BOERTH RC: Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. Clin. Pediatr. (2000) 39:213–220.
   PubMed Web of Science ®Google Scholar
• GARRISON MM, CHRISTAKIS DA, HARVEY E, CUMMINGS P, DAVIS RL: Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics (2000) 105:e44.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis suggesting a beneficial effect of corticosteroid treatment of RSV disease.
   Google Scholar
• VAN WOENSEL J, KIMPEN J: Therapy for respiratory tract infections caused by respiratory syncytial virus. Eur. Pediatr. (2000) 159:391–398.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis suggesting a beneficial effect of corticosteroid treatment of RSV disease.
   Google Scholar
• KAJOSAARI M, SYVANEN P, FORARS M, JUNTUNEN-BACKMAN K: Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma. Pediatr. Allergy 1177177L11701. (2000) 11:198–202.
   Google Scholar
• •Study suggesting that reactive airway disease following severe RSV infection may be reduced in patients treated with corticosteroids.
   Google Scholar
• BUCKINGHAM SC, JAFRI HS, BUSH AJ et al.: A random-ized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus infection: effects on viral load and clinical outcomes. Pediatr. Res. (2000) 47:257A.
   Web of Science ®Google Scholar
• BITKO V, VELAZQUEZ A, YANG L, YANG Y-C, BARIK S: Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-KB and is inhibited by sodium salicylate and aspirin. Virology (1997) 232:369–378.
   PubMed Web of Science ®Google Scholar
• TRIPP RA, MOORED, WINTER J, ANDERSON LJ: Respira-tory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. Viral. (2000) 74:1614–1622.
   PubMed Web of Science ®Google Scholar
• GINSBERG HS, MOLDAWER LL, SEHGAL PB et al.: A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Nat. Acad. Sci. USA (1991) 88:1651–1655.
   PubMed Web of Science ®Google Scholar
• SCHINAZI: U55824706 (1998).
   Google Scholar
• ABBOTT LAB.: U55866606 (1999).
   Google Scholar
• ABBOTT LAB.: U55981587 (1999).
   Google Scholar
• TRIMERIS, INC.: W09839287 (1998).
   Google Scholar
• VANDERBILT UNIV.: W09962932 (1999).
   Google Scholar
• AMERICAN CYANAMID CO.: U55852015 (1998).
   Google Scholar
• MEDIMMUNE INC.: U55824307 (1998).
   Google Scholar
• SOUTH ALABAMA MED. SCI. FDN.: U55831069 (1998).
   Google Scholar
• VANDERBILT UNIV./WRIGHT STATE UNIV.: W09812312 (1998).
   Google Scholar
• UCB: W09810764 (1998).
   Google Scholar
• BIOMOLECULAR RES. INST. LTD.: W09803572 (1998).
   Google Scholar
• VANDERBILT UNIV.: W09817321 (1998).
   Google Scholar